Eliot Park Innovation Centre
4 Barling Way
Nuneaton CV10 7RH
United Kingdom
44 24 7679 6496
https://www.valirx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 8
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. | CEO & Director | 160,85k | S.O. | 1978 |
Mr. James Gerry Desler FCA | CFO, Company Secretary & Executive Director | 53k | S.O. | 1945 |
Mr. Kumar Nawani | Head of Operations | S.O. | S.O. | S.O. |
Dr. Catherine Jane Tralau-Stewart Ph.D. | Chief Scientific Officer & Board Observer | S.O. | S.O. | S.O. |
Mr. Tarquin Edwards | Head of Investor Relations & Communications | S.O. | S.O. | S.O. |
Mr. Mark Treharne | Corporate Development Manager | S.O. | S.O. | S.O. |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.
L’ISS Governance QualityScore de ValiRx plc en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..